Analytical and Chemical Enhancements to Improve Efficacy and Accuracy of Therapeutic Oligonucleotides
See how top pharma players are addressing impure, unstable, and off-target oligos
Boosting the Efficacy of Safe, Scalable, & Precise Vaccines
Innovations in mRNA Technology, RNA Therapeutics, and Cancer Immunotherapy for 2024
.png)
Tumbler: A Highly Customizable Antibody Optimization Suite
On-demand presentation, presented by Michali Izhaky, Bioinformatics Scientist at Charles River
Leading Innovations in Fab, ScFv, & VHH Production and Engineering
On-demand webinar presented by Dr Jiansheng Wu, Head of Protein Sciences and Vice President at WuXi Biologics
Advancing Immunotherapy: The Critical Role of GMP-Grade Cytokines in Cell Therapy
On-demand webinar presented by Ritwika Biswas, Field Application Scientist at Sino Biological
Optimizing Bispecific Antibody Production: From Identifying Optimal Pairings to Scale-up Processes
On-demand webinar presented by Dr Jiansheng Wu, Head of Protein Sciences and Vice President at WuXi Biologics
Unlocking the Future of Immune Cancer Therapy
A concise report featuring insights from the prominent though leaders of Immuno 2024.
Manufacturing & Bioprocessing
Industry Insights Into the FDA's Plans for Revised Gene Therapy Approval Approaches
Some additional measures announced include the launch of the Cell and Gene Therapy Access Model, as well as the interpolation of RWE into trials and a potential move away from animal models in validating treatment efficacy.
Immuno-Oncology
Sensei Bio Presents Preclinical Data for Novel Antibody Therapeutic for Solid Tumours
Immuno-oncology company Sensei Bio gave a presentation which outlined convincing preclinical data for their novel antibody therapeutic.
Gene Therapy Development
FDA Pursues Accelerated Approval Path Following Cell and Gene Therapy Backlog
The announcement comes with the news that the cell and gene therapy manufacturing market is now worth US$ 19.3 billion, with a compound annual growth rate (CAGR) of 29% between 2022 and 2023.
Antibody & Protein Engineering
Computational Tools and AI/ML for Antibody Engineering
Opinion leaders from Merck and AbbVie discuss how antibody-based molecular engineering is developing with new AI/ML technologies.
Drug Discovery & Development
Therapy In the Spotlight: CAR T Cell Therapy—Significant Approvals and Regulatory Concerns
What are the regulatory considerations for CAR T cell therapy, and what's next for the approach?
NextGen Therapeutics
Biocon’s Biosimilar Difficulties: Successive FDA Rejections Don’t Inspire Hope
Biocon suffer another FDA rejection due to data and manufacturing concerns, this time for their bevacizumab biosimilar.
Jemperli Granted FDA Approval in Endometrial Cancer Applications
Following FDA approval for the use of Jemperli in the context of patients with dMMR recurrent or advanced scenarios, the therapeutic's applications are being investigated in registrational enabling studies as monotherapy and as part of combination regimens.
Immunotherapy (Non-Oncology)
Exploring the Role of IFNa in Autoimmunity & Infection
On-Demand Webinar featuring Dr Darragh Duffy, LabEx Coordinator at Institut Pasteur
The EMA’s Vaccines Working Party: The New Authority on Vaccines
The Vaccines Working Party was established last year by the EMA, but what are its main tasks, and how are they looking to achieve them?
Drug Discovery & Development
Novel TNF Superfamily Antagonists for Cancer & Autoimmunity
An interview with Russell LaMontagne, Co-Founder and Chief Executive Officer, Boston Immune Technologies and Therapeutics
Antibody & Protein Engineering
POLIVY vs ODAC: Can the Cancer Drug Score Another Indication?
The Oncologic Drugs Advisory Committee are preparing to weigh in on whether the FDA should grant another indication for Roche’s POLIVY.
Senti Streamline Their CAR-NK Cell Therapy Program to Focus on Acute Myeloid Leukaemia
By dropping down from three to two ongoing cell therapies in clinical development, Senti aims to ensure its current financial reserves last into 2024.